Converge Bio logo

Converge Bio

Emerging

Israeli AI drug discovery company raised $25M from Bessemer; 40+ active programs; CEO co-patented CRISPR technology with Jennifer Doudna;

Best for: AI Drug DiscoveryEmerging, rapid growth
38
AI Score
Grade D↑ Trending
AI Visibility Score (Beta)
HealthcareAI Drug DiscoveryWebsiteUpdated April 2026

Brand Intelligence Graph

Company Overview

About Converge Bio

Converge Bio is an Israeli AI drug discovery company using machine learning to design and optimize small molecule therapeutics across a broad portfolio of programs. Founded by a team with deep expertise in computational biology and medicinal chemistry, Converge has built a platform that combines AI-driven target identification, hit generation, and lead optimization into an integrated drug discovery engine. The company's scientific credibility is bolstered by its CEO, who co-patented CRISPR-related technology alongside Jennifer Doudna, a Nobel laureate and pioneer of gene editing.

Business Model & Competitive Advantage

Converge operates an unusually large portfolio by biotech standards, with 40+ active drug discovery programs spanning oncology, immunology, and other therapeutic areas. The company's AI platform is designed to generate high-quality small molecule candidates faster and at lower cost than traditional medicinal chemistry approaches, enabling it to maintain a broad pipeline without the typical resource constraints of running many programs in parallel. Converge uses structure-based design, generative chemistry, and predictive ADMET modeling to advance candidates from target to preclinical candidate stage.

Competitive Landscape 2025–2026

Converge raised $25M from Bessemer Venture Partners in January 2026, bringing external validation from one of Silicon Valley's most prominent technology-focused venture firms. The funding is being used to advance lead programs toward IND filings and expand the platform's capabilities. With 40+ programs and a Nobel laureate connection in its founding story, Converge represents Israel's growing position as a global hub for AI-driven drug discovery.

Curated content • Fact-checked and verified

Key Differentiators

Emerging Innovator

Converge Bio is an emerging player bringing innovative solutions to the Healthcare & Life Sciences market.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

38
↑ Trending

Based on estimated brand signals. Historical tracking coming soon.

Compare Converge Bio with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Converge Bio

Claim This Profile

Are you from Converge Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Converge Bio Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Converge Bio vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →